MedCity News

What’s Top of Mind for 3 Healthcare Execs on Deploying AI

Scaling Virtual Care Is Both a Moral and Financial Imperative, Sanford Health Exec Says

At MedCity News’ INVEST Digital Health conference, Sanford Health’s virtual care chief Dave Newman pointed out that in rural America, virtual care often determines whether patients receive treatment at all. He described how Sanford has expanded beyond video visits to include various other modalities like e-visit questionnaires, remote monitoring and even phone consults — saving patients time and money while also closing critical care gaps.

By Katie Adams

BioPharma, Startups

Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease

Dualitas Therapeutics designs bispecific antibodies to hit to two targets on the same immune cell, leveraging proximity biology to provide benefit beyond what’s possible with monoclonal antibody drugs. Eli Lilly and Chugai Pharmaceutical are among the investors in the immunology and inflammation startup.

By Frank Vinluan

MedCity Influencers

Why We Need to Rethink Private Practice Mental Health Care

No single provider should be expected to do everything, and no patient should have to navigate a fragmented system alone. A team-based model makes care more accessible, more effective, and more supportive for both patients and the providers who care for them.

By Colleen Marshall

Latest Video

Latest News

Health IT, MedCity Influencers

The Truth About Portals: Why Is Patient Usage so Low?

This stark reality raises an urgent question for health system executives: why aren’t patients engaging with these online tools, and how can we fix it?

By Suzie Sfarra

Top Story, Health Tech

AI in Healthcare: Investors’ Green and Red Flags Among Startups

During a panel discussion at the MedCity INVEST Digital Health conference, investors shared what they're looking for from AI startups and what their red flags are.

By Marissa Plescia

BioPharma, Pharma

Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition

Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller.

By Frank Vinluan

MedCity Influencers

Business guide to move to the right success direction, leadership to tell solution way, support, help or giving instruction concept, businessman with megaphone tell coworkers to walk the right way.

Why Insurers Need to Lead in the Shift to Healthcare Consumerism

We’re in the middle of a fundamental shift that’s giving consumers more power and choice over their health coverage while creating healthy competition in the marketplace. Consumer expectations are justifiably rising, and people want a much more pleasant, frictionless and digital experience from their health plan – just like they get everyplace else in their lives.

By Alan Stein

MedCity Influencers

Behind “Rise of Malingering” in ER Psychiatry: Why Better Patient Classification Matters

Malingering, deliberately feigning or exaggerating symptoms appears to be rising. This shift brings with it a tangled web of clinical, operational, and ethical challenges that affect not only providers but also the patients most in need of timely, effective care.

By Jim Szyperski

Health Tech

Do You Value MedCity News? Take Our Survey!

Take part in our Reader Survey and help us continue to grow!

By Stephanie Baum

Health Tech

Lōvu Health Rakes In $8M for Maternal Health Platform

Lōvu Health's Series A round was led by SJF Ventures and included participation from Rogue Women's Fund, Symphonic Capital, Emmeline Ventures and Majella Ventures.

By Marissa Plescia

Hospitals, Health Tech Artificial Intelligence,

Human bone full body with genomic DNA molecular structure and data on particle background.

Inside Duke’s Approach to Building and Buying AI Tools

Duke University Health System is deploying a mix of homegrown and purchased AI tools to ease clinicians’ administrative burden and improve patient care. Chief Nurse Executive Terry McDonnell highlighted that while AI can’t replace nurses’ judgment, it can help free up their time for what matters most.

By Katie Adams

BioPharma

GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years

President Trump has been pursuing policies intended to entice drugmakers to bring manufacturing and jobs to the U.S. GSK’s announcement makes it the latest big pharma company to unveil a multi-billion dollar plan for new U.S. facilities.

By Frank Vinluan

MedCity Influencers

Multi Layered Paper Craft Check Mark and Cross Mark in Concentric Circles on Green and Red Background Front View, Right or Wrong Choosing Concept.

The Delegation Dilemma: Why It’s Time for Health Plans to Rethink Vendor-Managed Utilization Management

As an industry, we need to ask hard questions. Are delegated vendors delivering on the promise of better, faster, more transparent decisions? Or are they simply moving the pain to another part of the system?

By Matt Cunningham

MedCity Influencers

Addressing the Primary Care Crisis by Integrating Advanced Practice Providers (APPs)

Since practices tend to build more flexibility into APPs’ schedules, they can efficiently expand patients’ access to care while allowing physicians to focus on more complex patients.

By Joe Nicholson

Payers, Providers

Harbor Health Secures $130M To Grow Insurance Plans and Clinical Footprint

Harbor Health's funding was co-led by General Catalyst, 8VC and Alta Partners. The round also includes participation from Dell Family Office Management, Health 2047 Capital Partners, Lemhi Ventures, Martin Ventures and Breyer Capital.

By Marissa Plescia